Maravai LifeSciences Holdings, Inc. Stock News

Maravai LifeSciences Holdings, Inc. (MRVI) CEO Carl Hull on Q1 2021 Results - Earnings Call Transcript

The sector's Q1 results are likely to reflect solid earnings and revenue growth on strong base business recovery.

SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans

SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovator

SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovator

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovator

SAN DIEGO, April 05, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai or the Company) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and bi

New integrated offering will help to meet expected increases in global demand by simplifying and accelerating production of GMP-grade mRNA product for downstream vaccine and therapeutic manufacturing

The stock price of Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) has increased by over 20% pre-market. This is why it happened.

Maravai LifeSciences Holdings, Inc. (MRVI) CEO Carl Hull on Q4 2020 Results - Earnings Call Transcript

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovator

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to

Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics Advancement Expected to Further Accelerate Development of mRNA Vaccines and Therapeutics

SAN DIEGO, Jan. 28, 2021 (GLOBE NEWSWIRE) -- Maravai LifeSciences , Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans

Maravai LifeSciences has received a welcome public debut. The company provides a crucial role in drug development and in fact even in the Pfizer/BioNTech vaccine.